-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
ProShare Advisors LLC Sells 6,933 Shares of CureVac (NASDAQ:CVAC)
ProShare Advisors LLC Sells 6,933 Shares of CureVac (NASDAQ:CVAC)
ProShare Advisors LLC reduced its holdings in shares of CureVac (NASDAQ:CVAC – Get Rating) by 26.4% during the first quarter, HoldingsChannel.com reports. The fund owned 19,377 shares of the company's stock after selling 6,933 shares during the quarter. ProShare Advisors LLC's holdings in CureVac were worth $380,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also bought and sold shares of CVAC. Capital Fund Management S.A. bought a new stake in CureVac during the fourth quarter worth $3,452,000. Eversept Partners LP bought a new stake in CureVac during the fourth quarter worth $2,917,000. Bank of America Corp DE lifted its holdings in CureVac by 246.6% during the fourth quarter. Bank of America Corp DE now owns 72,885 shares of the company's stock worth $2,501,000 after acquiring an additional 51,856 shares during the period. Schroder Investment Management Group bought a new stake in CureVac during the fourth quarter worth $1,413,000. Finally, Fosun International Ltd bought a new stake in shares of CureVac in the fourth quarter valued at $337,000.
Get CureVac alerts:Analysts Set New Price Targets
Separately, JMP Securities restated a "buy" rating and issued a $37.00 target price on shares of CureVac in a research note on Thursday, June 9th.
CureVac Stock Down 3.3 %
Shares of CVAC opened at $9.70 on Monday. The stock's fifty day moving average price is $13.14 and its two-hundred day moving average price is $15.71. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.39 and a current ratio of 3.45. CureVac has a 1 year low of $9.35 and a 1 year high of $71.63.CureVac Profile
(Get Rating)
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza.
See Also
- Get a free copy of the StockNews.com research report on CureVac (CVAC)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Want to see what other hedge funds are holding CVAC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CureVac (NASDAQ:CVAC – Get Rating).
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.
ProShare Advisors LLC reduced its holdings in shares of CureVac (NASDAQ:CVAC – Get Rating) by 26.4% during the first quarter, HoldingsChannel.com reports. The fund owned 19,377 shares of the company's stock after selling 6,933 shares during the quarter. ProShare Advisors LLC's holdings in CureVac were worth $380,000 as of its most recent filing with the Securities and Exchange Commission.
據HoldingsChannel.com報道,ProShare Advisors LLC在第一季度減持了26.4%的CureVac(納斯達克代碼:CVAC-GET評級)股票。該基金在本季度出售了6933股後,持有該公司19,377股股票。截至ProShare Advisors LLC最近提交給美國證券交易委員會(Securities And Exchange Commission)的文件,該公司持有的CureVac股份價值38萬美元。
A number of other hedge funds have also bought and sold shares of CVAC. Capital Fund Management S.A. bought a new stake in CureVac during the fourth quarter worth $3,452,000. Eversept Partners LP bought a new stake in CureVac during the fourth quarter worth $2,917,000. Bank of America Corp DE lifted its holdings in CureVac by 246.6% during the fourth quarter. Bank of America Corp DE now owns 72,885 shares of the company's stock worth $2,501,000 after acquiring an additional 51,856 shares during the period. Schroder Investment Management Group bought a new stake in CureVac during the fourth quarter worth $1,413,000. Finally, Fosun International Ltd bought a new stake in shares of CureVac in the fourth quarter valued at $337,000.
其他一些對衝基金也買賣了CVAC的股票。資本基金管理公司在第四季度購買了價值3,452,000美元的CureVac新股份。Eversept Partners LP在第四季度購買了價值291.7萬美元的CureVac新股份。去年第四季度,美國銀行(Bank Of America Corp DE)增持CureVac股份246.6%。美國銀行DE目前持有72,885股該公司股票,價值2,501,000美元,在此期間又購買了51,856股。施羅德投資管理集團在第四季度購買了價值1,413,000美元的CureVac新股份。最後,復星國際國際有限公司在第四季度購買了價值33.7萬美元的CureVac新股。
Analysts Set New Price Targets
分析師設定新的價格目標
Separately, JMP Securities restated a "buy" rating and issued a $37.00 target price on shares of CureVac in a research note on Thursday, June 9th.
另外,JMP證券在6月9日星期四的一份研究報告中重申了“買入”評級,併發布了CureVac股票的目標價為37.00美元。
CureVac Stock Down 3.3 %
CureVac股價下跌3.3%
CureVac Profile
CureVac配置文件
(Get Rating)
(獲取評級)
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza.
CureVac N.V.是一家臨牀階段的生物製藥公司,專注於開發基於信使核糖核酸(MRNA)的各種變革性藥物。它正在開發預防疫苗,如處於SARS-CoV-2第一階段臨牀試驗的mRNA候選疫苗CV2CoV;已完成狂犬病病毒糖蛋白第一階段臨牀試驗的基於mRNA的預防性疫苗CV7202;處於流感第一階段臨牀試驗的CVSQIV,以及拉沙熱、黃熱病、呼吸道合胞病毒、輪狀病毒、瘧疾和通用流感疫苗。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on CureVac (CVAC)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
- 免費獲取StockNews.com關於CureVac(CVAC)的研究報告
- 隨着管理層重組,股市能否迅速反彈?
- MarketBeat:回顧中的一週8/29-9/2
- 霍梅爾在這些水平上看起來很便宜
- 露露檸檬將飆升至9月
- 耐克股票會被超賣,但仍被高估嗎?
Want to see what other hedge funds are holding CVAC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CureVac (NASDAQ:CVAC – Get Rating).
想看看還有哪些對衝基金持有CVAC嗎?訪問HoldingsChannel.com獲取CureVac(納斯達克代碼:CVAC-GET Rating)的最新13F備案文件和內幕交易信息。
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.
接受CureVac Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對CureVac和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧